Compare CRMT & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRMT | QNCX |
|---|---|---|
| Founded | 1981 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.2M | 167.0M |
| IPO Year | 2026 | 2019 |
| Metric | CRMT | QNCX |
|---|---|---|
| Price | $18.31 | $0.10 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $37.00 | $10.00 |
| AVG Volume (30 Days) | 75.6K | ★ 127.2M |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 147.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,390,932,000.00 | N/A |
| Revenue This Year | $2.41 | N/A |
| Revenue Next Year | $4.65 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.78 | $0.09 |
| 52 Week High | $62.55 | $4.55 |
| Indicator | CRMT | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 29.93 | 27.44 |
| Support Level | $17.78 | N/A |
| Resistance Level | $28.59 | $0.98 |
| Average True Range (ATR) | 1.39 | 0.02 |
| MACD | -0.16 | 0.10 |
| Stochastic Oscillator | 16.16 | 12.47 |
America's Car-Mart Inc is an automotive retailer in the U.S. focused exclusively on the Integrated Auto Sales and Finance segment of the used car market. The company's operations are principally conducted through its two operating subsidiaries, America's Car Mart Inc and Colonial Auto Finance. It predominantly sells older model used vehicles and provides financing for substantially all of its customers. It earns revenue from the sale of used vehicles and, in the majority of cases, a related service contract and an accident protection plan product, as well as interest income and late fees from the related financing.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.